Bicuspid Aortic Valve (BAV)
Details of the Concept
Bicuspid aortic valve is the most common congenital valve malformation (prevalence ~1.5%), resulting from fusion or absence of valve leaflet progenitors during cardiac development. Although BAV typically functions normally until adulthood, affected individuals develop calcific aortic stenosis or aortic regurgitation at a younger age than those with trileaflet aortic valves. Almost all BAV patients require valve intervention during their lifetime.
Key Facts
Epidemiology
- Prevalence ~1.5% of the general population; unicuspid valve is rarer and likely underdiagnosed sources/vhd-mechanism-aha-2024 (very high)
- Male predominance at birth: 7.1/1000 male vs 1.9/1000 female (3–4× difference); persists to adulthood
- ~50% of all patients undergoing aortic valve replacement (AVR) for AS have BAV; BAV disease predominant in patients <60 years sources/vhd-mechanism-aha-2024 (very high)
- Associated with aortic dilatation in >50%; see also concepts/Aortic-Stenosis for clinical management
- Linked to Turner syndrome, Marfan syndrome, and Loeys-Dietz syndrome
Classification
- Two leaflets result from fusion or absence of progenitor populations during development
- Classified by orientation of leaflets (most commonly: right-left coronary cusp fusion; right-noncoronary fusion)
- Structural abnormalities in leaflets sometimes associated with aortic root dilation
Genetic Basis
- Heritability: up to 89% of cases show familial linkage; in most cases the specific genetic basis is unidentified — suggests complex (polygenic) pathology sources/vhd-mechanism-aha-2024 (very high)
- Known monogenic variants:
- NOTCH1 — endocardial-mesenchymal transition, valve development regulator
- GATA4, GATA5, GATA6 — transcription factors for cardiac development
- SMAD6 — BMP/TGF-β signaling mediator
- Genes associated with primary cilia and endothelial-mesenchymal transition
- Sex difference mechanism: reduced dosage of genes escaping X-chromosome inactivation proposed as contributing to male predominance; exact mechanism unknown
Pathobiology
- BAV leaflet structural abnormalities → abnormal flow patterns (turbulence, asymmetric shear stress) + abnormal stress-strain of leaflets
- These alterations → accelerated leaflet degeneration and calcification vs trileaflet aortic valves sources/vhd-mechanism-aha-2024 (very high)
- BAV CAVD may follow a similar molecular cascade as trileaflet CAVD but at an accelerated rate due to abnormal biomechanical environment — whether the calcification pattern differs between BAV and trileaflet AS is a key knowledge gap
Therapeutic Targets
- No medically accessible molecular targets for congenital valve malformations (the malformation is developmental and present from birth)
- Gene-targeted therapies for developmental pathways (NOTCH1, GATA4/5/6, SMAD6) are not currently clinically applicable
- Management remains surgical/transcatheter:
- TAVI for BAV stenosis at high surgical risk: Class IIb B (ESC 2025) if anatomy suitable per Heart Team sources/vhd-esc-2025 (very high)
- See concepts/Aortic-Stenosis and concepts/TAVI for full clinical management
Knowledge Gaps
- Are there preserved developmental pathways mediating congenital valve disease that could be targeted before birth or in infancy?
- Does the pattern of calcification in BAV-related AS differ from trileaflet calcific AS?
- Most cases have unidentified genetic basis — large-scale rare variant studies in diverse populations needed
Contradictions / Open Questions
- The biological mechanism driving the 3–4× male predominance (beyond X-chromosome inactivation gene dosage hypothesis) is not established sources/vhd-mechanism-aha-2024 (very high)
- Whether BAV patients should be managed differently from trileaflet AS patients in the early asymptomatic phase remains debated
Connections
- Related to concepts/Aortic-Stenosis — BAV is the dominant AS aetiology in patients <60 years; TAVI Class IIb for high surgical risk BAV
- Related to concepts/TAVI — anatomical considerations for BAV in TAVI selection
- Related to concepts/CAVD-Mechanisms — BAV accelerates the CAVD molecular cascade via abnormal shear stress
- Related to concepts/Valvular-Heart-Disease — VHD clinical overview
- Related to sources/vhd-mechanism-aha-2024